Moderna (MRNA) Stock Analysis & Winston Score
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus
Winston Score: 16/100 — Weak
Weak fundamentals across most pillars.
- Quality: Weak (1/30)
- Growth: Weak (1/20)
- Cash Flow: Weak (0/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Good (8/15)
Key Facts
Price: $61.82
Market Cap: $24.5B
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
